middle.news

Arovella Therapeutics Refreshes Board and CEO Amid Strategic Review

10:32am on Monday 4th of May, 2026 AEST Biotechnology
Read Story

Arovella Therapeutics Refreshes Board and CEO Amid Strategic Review

10:32am on Monday 4th of May, 2026 AEST
Key Points
  • CEO Dr Michael Baker resigns with three months' notice
  • Three directors resign immediately following shareholder requisition
  • New board of three members installed with David Williams as chairman
  • Company initiates comprehensive review of technology and growth strategy
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Arovella Therapeutics (ASX:ALA)
OPEN ARTICLE